InvestSMART

Amplia Therapeutics Limited (ASX:ATX)

ALERT: Price-sensitive ASX Announcement for ATX
Current share price for ATX : $0.130 -0.005 (-3.70%)+
Announcement
Release
4 Aug 2026 8:22AM
Price at Release
$0.135
Full Release
download
Summary
Amplia Therapeutics Limited has entered into a Clinical Trial Collaboration and Supply Agreement with Eli Lilly & Company to evaluate a combination therapy for non-small cell lung cancer (NSCLC). This collaboration involves Amplia's investigational FAK inhibitor, narmafotinib, and Lilly's KRAS G12C inhibitor, olomorasib. The Phase 1b/2b clinical trial aims to assess the safety and efficacy of this combination as a second-line treatment in NSCLC patients, marking an extension of Amplia's clinical focus beyond pancreatic and ovarian cancers. Conducted in Australia and the USA, this study is strategic for Amplia’s growth in oncology, leveraging narmafotinib's promising clinical data and Lilly's advanced KRAS inhibitor. The collaboration intends to address resistance in cancer therapies by integrating FAK inhibition with KRAS blockade, potentially expanding the treatment options for solid tumors with KRAS G12C mutations.
Key Points
  • Amplia and Lilly sign a collaboration and supply agreement.
  • The trial evaluates narmafotinib and olomorasib in NSCLC.
  • Study extends narmafotinib's use beyond pancreatic and ovarian cancers.
  • The trial will be conducted in Australia and the USA.
  • FAK is identified as a mediator of resistance to KRAS inhibition.
  • The collaboration is a strategic step for Amplia’s oncology expansion.
  • Lilly provides in-kind supply of olomorasib for the study.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.